SENSEX
NIFTY 50
Hang Seng
Taiwan Weighted
MCX GOLD DEC 05
MCX SILVER DEC 05
USD/INR
EUR/INR80.0630

SENSEX
NIFTY 50
NIFTY MIDCAP 100
S&P BSE MIDCAP
Hang Seng
Taiwan Weighted
DAX
Nasdaq
MCX GOLD DEC 05
MCX SILVER DEC 05
MCX CRUDEOIL NOV 16
MCX NATURALGAS OCT 26
USD/INR
EUR/INR
GBP/INR
JPY/INR

Stock Market Live Updates: Sensex trades higher, Nifty above 15,750 led by IT stocks; banks drag

Are Patek, AP and co. the new Blue-Chip stock? How certain timepieces are out performing financial markets

Oil rises for second day on signs of strong fuel demand recovery

Rupee surges 14 paise to 72.92 against US dollar in early trade

Niti Aayog’s VK Paul says decision to obtain stockpile of vaccine is dependent on licensure status

Updated : November 27, 2020 17:09:40 IST

On the vaccine front, there has been a lot of activity in the past few weeks, with various companies sharing the initial analysis of their trial data. American pharma giants Pfizer and Moderna, and Russia's RDIF have said that their vaccines have shown around 95 percent efficacy during trials. RDIF has also tied up with Hetero Pharma to manufacture Sputnik-V vaccines in India.

Serum Institute, the Indian manufacturing partner for Oxford vaccine, has also said that their vaccine is safe and effective. It has also stated that the Indian trials for the vaccine are running smoothly with strict adherence to all the necessary processes and protocols.

Oxford University and AstraZeneca, which had claimed up to 90 percent efficacy for their vaccine, have acknowledged that some of the vials used in their trial didn't have the right concentration of COVID vaccine so some volunteers got a half dose. But they added that the problem has been corrected -- AstraZeneca is now likely to conduct an additional global trial for its vaccine.

Doctor VK Paul, Member of NITI Aayog and Head, National Task Force on COVID-19, said, “There are exciting developments and we heard about two vaccines moving forward. We are also hearing that these vaccines and some others may also be seeking emergency licensure in their respective countries.”

“As of today there is no licensed vaccine which has crossed phase III satisfactorily with data being more available in the public domain so that is where today we are. We are fortunate that are own Indian vaccine candidate are moving forward satisfactorily.”

He also said, “The decision to obtain a particular stock pile of the vaccine is dependent upon the licensure first and foremost and that is a technical process.”

To know more, watch this video.

Published : November 27, 2020 05:09 PM IST

You May Also Like

PPF vs NPS: How much should you invest to earn Rs 1 crore?

PPF vs NPS: How much should you invest to earn Rs 1 crore?

New IFSC codes and cheque books for Syndicate Bank customers from July 1

New IFSC codes and cheque books for Syndicate Bank customers from July 1

Vaccine shortage should end by next week; aim to immunise 1 crore people every day, says Dr NK Arora

Vaccine shortage should end by next week; aim to immunise 1 crore people every day, says Dr NK Arora

Trending on CNBC-TV18

Live TV

recommended for you